Health Care • Medical/Dental Instruments
$0.96 ▼ -0.02
(-2.13%)
MKT CAP: $3.3M • VOL: 56.7K
52W L $1 52W H $23
ROARABLE / RQD
D • 46/100
PIOTROSKI
5 / 9
ICCM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.4M | $3.3M | $3.2M |
| YoY Revenue Growth % | +2.7% | +1.9% | — |
| Gross Profit | $1.2M | $1.5M | — |
| Gross Margin % | 36.3% | 44.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$15.1M | -$15.7M | -$15.6M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$15.1M | -$15.3M | -$14.7M |
| EBITDA (Normalized) | -$15.1M | -$15.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$14.6M | -$12.6M | -$12.6M |
| Capital Expenditures (CapEx) | $36.0K | $71.0K | — |
| Free Cash Flow (FCF) | -$14.6M | -$12.6M | -$12.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.9M | $7.6M | — |
| Total Debt (Short + Long Term) | $13.0K | $161.0K | — |
| Total Stockholders' Equity | $9.1M | $6.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ICCM.